Cytosorbents Crp (NASDAQ: CTSO) — Perfil da empresa, notícias e dados financeiros
Cytosorbents develops CytoSorb, a blood purification technology aimed at controlling inflammation in critically ill patients.
Cytosorbents Crp
Cytosorbents (NASDAQ:CTSO) is a medical technology company focused on developing and commercializing its flagship product, CytoSorb, a blood purification technology aimed at controlling severe inflammation in critically ill and cardiac surgery patients. The technology is designed to filter out inflammatory toxins and substances from the blood to help patients recover from conditions that can lead to organ failure. The company is deeply involved in research and clinical studies to expand the application of CytoSorb for various medical emergencies and conditions, striving to save lives and improve outcomes for critically ill patients. Their objective is to continuously innovate and extend their reach to more patients globally, enhancing the effectiveness of critical care through their advanced treatment options.
Resumo
Operações
Produtos e/ou serviços de Cytosorbents Crp
- CytoSorb, a blood purification technology aimed at reducing deadly inflammation and preventing or treating organ failure.
- Cardiac surgery programs designed to reduce the risks and complications associated with heart surgeries.
- Critical Care programs focused on treating sepsis, burn injuries, and trauma cases.
- DrugSorb-ATR, an antithrombotic removal device targeting the prevention of bleeding complications in cardiac surgeries.
- K+ontrol, a product designed for the management of hyperkalemia, aiming to prevent the deadly risks of high potassium levels.
- Veterinary programs, developing treatments tailored for life-threatening conditions in animals.
equipe executiva do Cytosorbents Crp
- Phillip P. ChanCEO & Director
- Vincent J. CapponiPresident & COO
- Peter J. MarianiChief Financial Officer
- Efthymios N. DeliargyrisChief Medical Officer
- Christian SteinerExecutive Vice President of Sales & Marketing
- Christopher CramerSenior Vice President of Business Development
- Kathleen P. BlochAdvisor
- Jodi HooverExecutive
- Robert H. BartlettCo-Chairman of Cardiac Surgery Advisory Board & Consultant
Principais indicadores financeiros
Resultados divulgados pela Cytosorbents Crp, em USD.
- Cap. de mercado
- 16,5 mi
- Receita (TTM)
- 37,2 mi
- P/L
- —
- LPA (diluído, TTM)
- -6.3
- Dividend yield
- —
- Margem de lucro
- -48.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 37,1 mi | -14,2 mi | -8,2 mi | |
| 35,6 mi | -16,5 mi | -20,7 mi | |
| 31,1 mi | -31,9 mi | -29,2 mi | |
| 34,7 mi | -31,5 mi | -32,8 mi |